Welcome to our dedicated page for GREY MATTERS HEALTH INC, news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on GREY MATTERS HEALTH INC, stock.
Grey Matters Health Inc., formerly Algernon Health Inc. and Algernon Pharmaceuticals Inc., reports healthcare developments tied to its shift toward Alzheimer’s disease diagnostics and dedicated brain PET imaging. News for AGNPF has centered on NovaScan Neuroimaging Clinics, U.S. brain PET scanning center plans, CareMiBrain™ scanner technology, beta-amyloid detection, and clinical uses across dementia and other neurologic conditions.
Company updates also cover capital-structure actions, including name changes and share consolidation, equipment financing, service partnerships, clinic leases, and shareholder or governance matters. The company has also described Algernon NeuroScience’s regulated botanical wellness program involving a proprietary form of DMT and its equity interest in Seyltx, which is advancing Ifenprodil for chronic cough.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) has filed a scientific advice meeting request with the UK's MHRA for a Phase 1/2a stroke study involving DMT, a psychedelic compound. The planned CTA application is set for Q4 2021. The study aims to assess safety and pharmacokinetics of DMT and its potential as an adjunctive treatment with Constraint-Induced Movement Therapy for stroke patients. Notably, preclinical trials indicated a 40% increase in cortical neuron growth using a sub hallucinogenic dose of DMT.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has filed a pre-IND meeting request with the U.S. FDA for its NP-120 (Ifenprodil) aimed at treating refractory chronic cough. This potential first-in-class treatment shows promising trends from an interim analysis of its ongoing Phase 2 study in Australia and New Zealand. Results revealed a significant reduction in cough counts after 12 weeks. Depending on FDA feedback, the U.S. Phase 2 study could begin in Q2 2022. Chronic cough, affecting 10% of adults, currently has no approved therapies.
Algernon Pharmaceuticals has filed a pre-IND meeting request with the U.S. FDA for its clinical program investigating NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC). This marks a significant step in the development of Ifenprodil, which shows promise when combined with Topotecan to inhibit tumor growth. SCLC accounts for 15% of lung cancers, with limited treatment options available for patients suffering from this condition. CEO Christopher J. Moreau expressed optimism about advancing the SCLC program rapidly, emphasizing the urgent need for new treatment avenues.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announces the appointment of Dr. Mark Williams to its Board of Directors, succeeding Michael Sadhra, who resigned to pursue other ventures. Dr. Williams, a co-founder of the company's drug repurposing program, has over 15 years of experience in drug development. He holds a PhD in Microbiology and an MBA. CEO Christopher J. Moreau welcomes his extensive knowledge in pre-clinical and clinical development, enhancing the board's expertise.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) has announced plans to file a pre-IND meeting request with the FDA for a Phase 2 chronic cough study using NP-120 (Ifenprodil). The decision to expand the Ifenprodil research stems from positive interim data from a Phase 2 trial on idiopathic pulmonary fibrosis (IPF) and chronic cough. Preliminary results indicated a relative reduction in cough counts in patients, and the new study aims to focus solely on chronic cough, powered for statistical significance, with a placebo control.
Algernon Pharmaceuticals announced that CEO Christopher J. Moreau will give a keynote presentation at the Microdose Virtual 2021 DMT Conference on September 9th. Moreau's talk, titled “DMT – New Hope for Healing the Brain After a Stroke,” will present Algernon's unique clinical research program focused on DMT for stroke treatment. The preliminary study revealed that DMT increased the growth of cortical neurons by 40% at sub-hallucinogenic doses. Algernon aims to be the first to test DMT for stroke in humans, and has filed new provisional patents related to its treatment.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced the appointment of Harry Bloomfield, QC, as a new Board member and Chairman. Bloomfield brings significant experience as a lawyer and business manager, with a history in senior business roles and board memberships across various entities. His expertise is expected to enhance Algernon's drug repurposing initiatives. CEO Christopher Moreau expressed confidence in Bloomfield's ability to contribute positively to the company's strategic goals.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced successful results from its preclinical study on AP-188 (DMT), showing a 40% increase in cortical neuron growth with statistical significance using a sub-hallucinogenic dose. Conducted by Charles River Laboratories, the study aims to explore DMT's neuroplastic effects for stroke treatment with minimal side effects. The next phase involves analyzing treatment duration from 1 to 72 hours, with results expected by October 2021. Algernon aims to lead human trials for DMT targeting ischemic stroke.
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced the initiation of an NP-120 (Ifenprodil) research program for small cell lung cancer (SCLC) and appointed Dr. William North as lead consultant. Ifenprodil, shown to inhibit tumor growth in previous studies, was tested in combination with chemotherapy and demonstrated significant additive effects. The company signed a licensing agreement with Dartmouth College for a method of use patent related to neuroendocrine cancers and plans to submit a pre-IND meeting request to the FDA for SCLC clinical program guidance.
Algernon Pharmaceuticals has signed an exclusive licensing agreement with Dartmouth College for a method of use patent targeting neuroendocrine cancers that express functional NMDA receptors. The licensing deal includes a fee structure and ongoing royalties on sales. Algernon aims to leverage Ifenprodil, which has shown significant anti-tumor effects in pancreatic cancer models, to progress into clinical trials. The company plans to submit a pre-IND meeting request to the FDA for guidance on its clinical program design, emphasizing its commitment to advancing cancer treatment.